APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Dendritic Cell Cancer Vaccine Immunotherapy

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Dendritic Cell Cancer Vaccine Immunotherapy Industry Growth and Trends Forecast to 2032

Report ID 173982990129 December 2025104 pages

Choose your research edition.

Industry ResearchDendritic Cell Cancer Vaccine Immunotherapy Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Dendritic Cell Cancer Vaccine Immunotherapy Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Dendritic Cell Cancer Vaccine Immunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dendritic Cell Cancer Vaccine Immunotherapy Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Dendritic Cell Cancer Vaccine Immunotherapy Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

According to APO Research, the global Dendritic Cell Cancer Vaccine Immunotherapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Dendritic Cell Cancer Vaccine Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Dendritic Cell Cancer Vaccine Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dendritic Cell Cancer Vaccine Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Dendritic Cell Cancer Vaccine Immunotherapy market include AVAX Technologies, DCPrime, Gradalis, Heat Biologics, Immunicum, ImmunoCellular Therapeutics, Lineage Cell Therapeutics, MolecuVax and Northwest Biotherapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Dendritic Cell Cancer Vaccine Immunotherapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Dendritic Cell Cancer Vaccine Immunotherapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Dendritic Cell Cancer Vaccine Immunotherapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Dendritic Cell Cancer Vaccine Immunotherapy.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Dendritic Cell Cancer Vaccine Immunotherapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Dendritic Cell Cancer Vaccine Immunotherapy Market by Company

AVAX Technologies

DCPrime

Gradalis

Heat Biologics

Immunicum

ImmunoCellular Therapeutics

Lineage Cell Therapeutics

MolecuVax

Northwest Biotherapeutics

Pique Therapeutics

Regeneus

Tessa Therapeutics

Vaccinogen

XEME Biopharma

Dendritic Cell Cancer Vaccine Immunotherapy Segment by Type

Provenge

CreaVax

Apceden

Others

Dendritic Cell Cancer Vaccine Immunotherapy Segment by Application

Pediatrics

Adults

Dendritic Cell Cancer Vaccine Immunotherapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dendritic Cell Cancer Vaccine Immunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dendritic Cell Cancer Vaccine Immunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dendritic Cell Cancer Vaccine Immunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Dendritic Cell Cancer Vaccine Immunotherapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2021-2026) Table 4. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2027-2032) Table 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Type (2021-2026) Table 9. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share Forecasted by Type (2027-2032) Table 11. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Application (2021-2026) Table 24. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share Forecasted by Application (2027-2032) Table 26. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Dendritic Cell Cancer Vaccine Immunotherapy Industry Trends Table 37. Dendritic Cell Cancer Vaccine Immunotherapy Industry Drivers Table 38. Dendritic Cell Cancer Vaccine Immunotherapy Industry Opportunities and Challenges Table 39. Dendritic Cell Cancer Vaccine Immunotherapy Industry Restraints Table 40. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Dendritic Cell Cancer Vaccine Immunotherapy Revenue Market Share by Company (2021-2026) Table 42. Global Dendritic Cell Cancer Vaccine Immunotherapy Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Dendritic Cell Cancer Vaccine Immunotherapy Key Company Headquarters & Area Served Table 44. Global Dendritic Cell Cancer Vaccine Immunotherapy Company, Product Type & Application Table 45. Global Dendritic Cell Cancer Vaccine Immunotherapy Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Dendritic Cell Cancer Vaccine Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. AVAX Technologies Company Information Table 49. AVAX Technologies Business Overview Table 50. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 52. AVAX Technologies Recent Development Table 53. DCPrime Company Information Table 54. DCPrime Business Overview Table 55. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 57. DCPrime Recent Development Table 58. Gradalis Company Information Table 59. Gradalis Business Overview Table 60. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 62. Gradalis Recent Development Table 63. Heat Biologics Company Information Table 64. Heat Biologics Business Overview Table 65. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 67. Heat Biologics Recent Development Table 68. Immunicum Company Information Table 69. Immunicum Business Overview Table 70. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 72. Immunicum Recent Development Table 73. ImmunoCellular Therapeutics Company Information Table 74. ImmunoCellular Therapeutics Business Overview Table 75. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 77. ImmunoCellular Therapeutics Recent Development Table 78. Lineage Cell Therapeutics Company Information Table 79. Lineage Cell Therapeutics Business Overview Table 80. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 82. Lineage Cell Therapeutics Recent Development Table 83. MolecuVax Company Information Table 84. MolecuVax Business Overview Table 85. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 87. MolecuVax Recent Development Table 88. Northwest Biotherapeutics Company Information Table 89. Northwest Biotherapeutics Business Overview Table 90. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 92. Northwest Biotherapeutics Recent Development Table 93. Pique Therapeutics Company Information Table 94. Pique Therapeutics Business Overview Table 95. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 97. Pique Therapeutics Recent Development Table 98. Regeneus Company Information Table 99. Regeneus Business Overview Table 100. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 102. Regeneus Recent Development Table 103. Tessa Therapeutics Company Information Table 104. Tessa Therapeutics Business Overview Table 105. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 107. Tessa Therapeutics Recent Development Table 108. Vaccinogen Company Information Table 109. Vaccinogen Business Overview Table 110. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 112. Vaccinogen Recent Development Table 113. XEME Biopharma Company Information Table 114. XEME Biopharma Business Overview Table 115. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio Table 117. XEME Biopharma Recent Development Table 118. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 120. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2026) Table 121. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share Forecast by Country (2027-2032) Table 123. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 125. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2026) Table 126. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share Forecast by Country (2027-2032) Table 128. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 130. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2026) Table 131. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share Forecast by Country (2027-2032) Table 133. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 135. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2026) Table 136. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share Forecast by Country (2027-2032) Table 138. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026) & (US$ Million) Table 140. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2026) Table 141. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share Forecast by Country (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Dendritic Cell Cancer Vaccine Immunotherapy Product Image Figure 3. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2021-2032) & (US$ Million) Figure 5. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region: 2025 VS 2032 Figure 6. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Region (2021-2032) Figure 7. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Provenge Image Figure 13. Global Provenge Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. CreaVax Image Figure 15. Global CreaVax Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Apceden Image Figure 17. Global Apceden Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Others Image Figure 19. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Type 2025 VS 2032 Figure 22. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Type (2021-2032) Figure 23. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Type (2021-2032) Figure 25. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Type (2021-2032) Figure 27. Pediatrics Image Figure 28. Global Pediatrics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Adults Image Figure 30. Global Adults Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Application 2025 VS 2032 Figure 33. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Application (2021-2032) Figure 34. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Application (2021-2032) Figure 36. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Dendritic Cell Cancer Vaccine Immunotherapy Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2032) Figure 43. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2032) Figure 46. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2032) Figure 49. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2032) Figure 52. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Provenge
  • CreaVax
  • Apceden
  • Others
Applications
  • Pediatrics
  • Adults
Companies covered
  • AVAX Technologies
  • DCPrime
  • Gradalis
  • Heat Biologics
  • Immunicum
  • ImmunoCellular Therapeutics
  • Lineage Cell Therapeutics
  • MolecuVax
  • Northwest Biotherapeutics
  • Pique Therapeutics
  • Regeneus
  • Tessa Therapeutics
  • Vaccinogen
  • XEME Biopharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2021-2032)
  5. 1.4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2021-2026)
  6. 1.4.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2027-2032)
  7. 1.5 Key Regions Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2021-2032)
  8. 1.5.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (2021-2032)
2 Dendritic Cell Cancer Vaccine Immunotherapy Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Provenge
  3. 2.1.2 CreaVax
  4. 2.1.3 Apceden
  5. 2.1.4 Others
  6. 2.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type
  7. 2.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Regions
  11. 2.3.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Type (2021-2026)
3 Dendritic Cell Cancer Vaccine Immunotherapy Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Pediatrics
  3. 3.1.2 Adults
  4. 3.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application
  5. 3.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Regions
  9. 3.3.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Dendritic Cell Cancer Vaccine Immunotherapy Industry Trends
  2. 4.2 Dendritic Cell Cancer Vaccine Immunotherapy Industry Drivers
  3. 4.3 Dendritic Cell Cancer Vaccine Immunotherapy Industry Opportunities and Challenges
  4. 4.4 Dendritic Cell Cancer Vaccine Immunotherapy Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Dendritic Cell Cancer Vaccine Immunotherapy Revenue (2021-2026)
  2. 5.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Key Company Headquarters & Area Served
  4. 5.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Company, Product Type & Application
  5. 5.5 Global Dendritic Cell Cancer Vaccine Immunotherapy Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Dendritic Cell Cancer Vaccine Immunotherapy Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Dendritic Cell Cancer Vaccine Immunotherapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 AVAX Technologies
  2. 6.1.1 AVAX Technologies Company Information
  3. 6.1.2 AVAX Technologies Business Overview
  4. 6.1.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  6. 6.1.5 AVAX Technologies Recent Developments
  7. 6.2 DCPrime
  8. 6.2.1 DCPrime Company Information
  9. 6.2.2 DCPrime Business Overview
  10. 6.2.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  12. 6.2.5 DCPrime Recent Developments
  13. 6.3 Gradalis
  14. 6.3.1 Gradalis Company Information
  15. 6.3.2 Gradalis Business Overview
  16. 6.3.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  18. 6.3.5 Gradalis Recent Developments
  19. 6.4 Heat Biologics
  20. 6.4.1 Heat Biologics Company Information
  21. 6.4.2 Heat Biologics Business Overview
  22. 6.4.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  24. 6.4.5 Heat Biologics Recent Developments
  25. 6.5 Immunicum
  26. 6.5.1 Immunicum Company Information
  27. 6.5.2 Immunicum Business Overview
  28. 6.5.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  30. 6.5.5 Immunicum Recent Developments
  31. 6.6 ImmunoCellular Therapeutics
  32. 6.6.1 ImmunoCellular Therapeutics Company Information
  33. 6.6.2 ImmunoCellular Therapeutics Business Overview
  34. 6.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  36. 6.6.5 ImmunoCellular Therapeutics Recent Developments
  37. 6.7 Lineage Cell Therapeutics
  38. 6.7.1 Lineage Cell Therapeutics Company Information
  39. 6.7.2 Lineage Cell Therapeutics Business Overview
  40. 6.7.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  42. 6.7.5 Lineage Cell Therapeutics Recent Developments
  43. 6.8 MolecuVax
  44. 6.8.1 MolecuVax Company Information
  45. 6.8.2 MolecuVax Business Overview
  46. 6.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  48. 6.8.5 MolecuVax Recent Developments
  49. 6.9 Northwest Biotherapeutics
  50. 6.9.1 Northwest Biotherapeutics Company Information
  51. 6.9.2 Northwest Biotherapeutics Business Overview
  52. 6.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  54. 6.9.5 Northwest Biotherapeutics Recent Developments
  55. 6.10 Pique Therapeutics
  56. 6.10.1 Pique Therapeutics Company Information
  57. 6.10.2 Pique Therapeutics Business Overview
  58. 6.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  60. 6.10.5 Pique Therapeutics Recent Developments
  61. 6.11 Regeneus
  62. 6.11.1 Regeneus Company Information
  63. 6.11.2 Regeneus Business Overview
  64. 6.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  66. 6.11.5 Regeneus Recent Developments
  67. 6.12 Tessa Therapeutics
  68. 6.12.1 Tessa Therapeutics Company Information
  69. 6.12.2 Tessa Therapeutics Business Overview
  70. 6.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  72. 6.12.5 Tessa Therapeutics Recent Developments
  73. 6.13 Vaccinogen
  74. 6.13.1 Vaccinogen Company Information
  75. 6.13.2 Vaccinogen Business Overview
  76. 6.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  78. 6.13.5 Vaccinogen Recent Developments
  79. 6.14 XEME Biopharma
  80. 6.14.1 XEME Biopharma Company Information
  81. 6.14.2 XEME Biopharma Business Overview
  82. 6.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Product Portfolio
  84. 6.14.5 XEME Biopharma Recent Developments
7 North America
  1. 7.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
  3. 7.3 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
  3. 8.3 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
  3. 10.3 South America Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst